DIGITAL TRANSFORMATION OF ASTELLAS PHARMA

Media Briefing - January 21, 2022

Cautionary Statement Regarding Forward-Looking Information

2

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches,

  1. the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
    Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

Agenda

3

Reasons to Engage in Digital Transformation

1 Naoki Okamura

Chief Strategy Officer and Chief Financial Officer, Chief Business Officer

Digital Transformation of Astellas Pharma

2 Shinya Suda

Senior Vice President, Information Systems

Reasons to Engage in Digital Transformation

Naoki Okamura

Chief Strategy Officer and Chief Financial Officer, Chief Business Officer

Vision

5

Vision

On the Forefront of

Healthcare Change to Turn

Innovative Science into

VALUE for

Patients

We will achieve sustainable

growth by pursuing innovative

science to produce medical

solutions that provide VALUE

to patients

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Astellas Pharma Inc. published this content on 21 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 January 2022 01:11:04 UTC.